Scientific Aim

The Landsteiner Foundation for Blood Transfusion Research (LSBR) supports fundamental research, including clinical and experimental investigations, in the field of blood, blood derivatives, and blood (related) diseases, provided that these are related to transfusion or blood cell transplantation.

This scope spans a wide range of subjects in the field of hematology, including haematopoiesis, haemostasis, immunotherapy, transfusion medicine, and other issues relevant to the field.


News

In 2021 a Dutch translation of the book Surviving Haemophilia, the business case of a disease written by Cees Smit became available.
The book tells the story of Cees Smit, who was born with hemophilia A almost seventy years ago. No one ever expected him to survive long into adulthood, much less old age. He survived all stages of medical innovations, with both highlights and drawbacks. Today he is a lobbyist for patients’ rights and the improvement of patients’ position in the healthcare system. The book also serves as a strong plee for European self-sufficiency in ‘red’ and ‘white’ plasma from voluntary non-remunerated donors. It is disturbing that today’s policy makers pay so little attention to the world of blood transfusion and plasma products. In a neoliberal market economy, the trade in human substances is too easily accepted.
Publication was supported by a grant from the LSBR.
ISBN: 9789463012911


In November 2021 the book Els Borst, medicus in de politiek written by Nele Beyens was published by De Park Uitgeverij / Wereldbibliotheek. The presentation was on November the 5-th and publication was supported by grants from Amsterdam UMC, location AMC, ZonMW, Sanquin, de Hollandsche Maatschappij der Wetenschappen, UMC Utrecht and the LSBR.
The book is in Dutch.
ISBN: 9789028451483.


Pre-applications 2022

Submission for Pre-Applications for Scientific Research 2022 is closed.


Granted in 2021

2103 – Dr. M. Wolkers/Dr. Branka Popović: Dissecting the interplay between RNA binding proteins and transcription factors in shaping T cell differentiation.
Budget: euro 463,783; Project duration: 3 years

2107 – Dr. J. Garaycoechea: Mapping sources of genome instability during hematopoiesis.
Budget: euro 418,390; Project duration: 4 years

2112 – Dr. M. Themeli/Dr. M. Hansen/Dr. C. Voermans: Induced pluripotent stem cells as a source of efficient and durable “off-the-shelf” CAR T cells for the treatment of cancer.
Budget: euro 492,882; Project duration: 3 years

2114 – Dr. G. Vidarsson/Dr. R. Kapur/Dr. M.D. Hazenberg: IgG-glycosylation and hexamerization as sweet spots in alloimmune responses against blood cells.
Budget: euro 480,603; Project duration: 4 years

2125 – Dr. D. Amsen: How inflammation turns regulatory T cell function on and off.
Budget: euro 452,228; Project duration: 3 years


History

In 1948 the Dutch government, the Dutch Red Cross and the municipality of Amsterdam founded the Central Laboratory of the Blood Transfusion Service of the Netherlands Red Cross (CLB) and installed its supporting foundation the Stichting tot Instandhouding van het CLB (StICLB). For 50 years this foundation supported the activities of CLB, including research in the field of blood transfusion and the manufacturing of plasma products. Its board acted as the supervisory board of CLB.

In 1998 CLB merged with the 22 Dutch regional blood banks into a new foundation, i.e. Sanquin Blood Supply Foundation. The merger did not include StICLB, which needed to adapt its statutes to ensure that the (financial) assets of StICLB remained available for continued support of the research in the field of blood and blood transfusion in The Netherlands. The name of StICLB was changed to Landsteiner Stichting voor Bloedtransfusieresearch (LSBR). The LSBR is an independent foundation that uses the revenues of its assets to support research proposals from Sanquin and other Dutch institutes in the same field.

Article 3 of the LSBR statutes of 17 April 2015 specifies the objectives of LSBR:

  • to support scientific research, especially basic research, in blood transfusion and related subjects
  • to fulfill moral and social obligations, especially obligations originating from the history of the foundation
  • to manage the financial assets of the foundation.